Figure 5. Anti-CD154 Ab treatment attenuates acute cellular rejection and abrogates CD8⁺ and CD4⁺ allospecific effector responses following mouse orthotopic lung transplant.

(A) Representative day 10 gross pathology of an allograft from an anti-CD154 Ab-treated mouse and (B) lung allograft histology of untreated and anti-CD154 Ab-treated mice. (C) Acute rejection pathology score means in allografts of untreated versus anti-CD154 treated mice (n=4 mice per group). (D) Comparison of mean mononuclear cell recoveries at day 10 in untreated versus anti-CD154 Ab-treated mice (n=4–6 per group). (E) Representative flow plots of day 10 CD8⁺ IFN-γ responses in lung mononuclear cells from allograft of untreated mouse versus anti-CD154 Ab -treated mouse after 5h culture conditions of medium alone, in the presence of BALB/c splenocytes (1:1 ratio), or with PMA/ionomycin; gating on H-2^d negative, CD8⁺ T cells in mixed cultures. (F) Cumulative mean allospecific CD8⁺ and CD4⁺ IFN-γ responses (expressed as percent of cells positive for IFN-γ) from lung allografts of both groups after 5h culture of lung mononuclear cells with BALB/c splenocytes (n=4–6 mice per group).